Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 2/2016

01-02-2016 | Research Article

Serum nectin-2 levels are diagnostic and prognostic in patients with colorectal carcinoma

Authors: M. Karabulut, M. Gunaldi, H. Alis, C. U. Afsar, S. Karabulut, M. Serilmez, C. Akarsu, H. Seyit, N. F. Aykan

Published in: Clinical and Translational Oncology | Issue 2/2016

Login to get access

Abstract

Introduction

Nectins are a family of integral protein and immunoglobulin-like cell adhesion molecules involved in the formation of functioning adherence and tight junctions. Aberrant expression is associated with cancer progression, apoptosis and cell proliferation but little is known how these effects change in cell behavior. The objective of this study was to evaluate the serum levels of nectin-2 with regard to diagnostic, predictive and prognostic value in colorectal cancer (CRC) patients.

Materials and methods

One-hundred and forty CRC patients were enrolled in this study. Serum nectin-2 levels were determined by enzyme-linked immunosorbent assay method. Age- and sex-matched 40 healthy controls were included in the analysis.

Results

Median age of patients was 60 years old, range 24–84 years. The localization of tumor in majority of the patients was colon (n = 81, 58 %). Non-metastatic (stage II and III) and metastatic patients’ baseline serum nectin-2 levels were significantly higher than those in the healthy control group (p < 0.001; for two group). However, known clinical variables including response to CTx (chemotherapy) were not found to be correlated with serum nectin-2 concentrations (p > 0.05). While non-metastatic group patients with elevated serum nectin-2 levels showed significant adverse effect on PFS, metastatic group patients with elevated serum nectin-2 levels showed no significant adverse effect on PFS (p = 0.05 and p = 0.29, respectively). On the other hand, our study results did not show statistically significant serum nectin-2 concentrations regarding overall survival rates.

Conclusion

Serum levels of nectin-2 may have diagnostic roles for CRC patients. Moreover, our study results show the prognostic role of nectin-2 in non-metastatic group patients.
Literature
1.
Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64:104–17.CrossRefPubMed
2.
Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010;375:1030–47.CrossRefPubMed
3.
Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC, et al. Current opinion on optimal treatment for colorectal cancer. Expert Rev Anticancer Ther. 2013;13:597–611.CrossRefPubMed
4.
5.
Ren F, Wang L, Shen X, Xiao X, Liu Z, Wei P, et al. MYBL2 is an independent prognostic marker that has tumor-promoting functions in colorectal cancer. Am J Cancer Res. 2015;5(4):1542–52.PubMedCentralPubMed
6.
Su CY, Lin TC, Lin YF, Chen MH, Lee CH, Wang HY, et al. DDX3 as a strongest prognosis marker and its downregulation promotes metastasis in colorectal cancer. Oncotarget. 2015 [Epub ahead of print].
7.
Ozawa T, Ishihara S, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, et al. The preoperative platelet to lymphocyte ratio is a prognostic marker in patients with stage II colorectal cancer. Int J Colorectal Dis. 2015 [Epub ahead of print].
8.
Chen YT, Tsao SC, Yuan SS, Tsai HP, Chai CY. Serine protease ınhibitor Kazal type 1 (SPINK1) promotes proliferation of colorectal cancer through the epidermal growth factor as a prognostic marker. Pathol Oncol Res. 2015 [Epub ahead of print].
9.
Hu Y, Yi B, He S, Liu P, Wang L, Yu J, et al. Clinical significance of miR-1826 as a novel prognostic biomarker in colorectal cancer. Anticancer Agents Med Chem. 2015 [Epub ahead of print].
10.
Kahlert C, Lerbs T, Pecqueux M, Herpel E, Hoffmeister M, Jansen L, et al. Overexpression of SIX1 is an independent prognostic marker in stage I–III colorectal cancer. Int J Cancer. 2015. doi:10.​1002/​ijc.​29596.
11.
Liu G, Zhu J, Yu M, Cai C, Zhou Y, Yu M, et al. Glutamate dehydrogenase is a novel prognostic marker and predicts metastases in colorectal cancer patients. J Transl Med. 2015;13:144.PubMedCentralCrossRefPubMed
12.
Koch C, Trojan J. Established and potential predictive biomarkers in gastrointestinal cancer-c-Kit, Her2, Ras and Beyond. Digestion. 2015;91(4):294–302.CrossRefPubMed
13.
Sakisaka T, Takai Y. Biology and pathology of nectins and nectin-like molecules. Curr Opin Cell Biol. 2004;16:513–21.CrossRefPubMed
14.
Sakisaka T, Ikeda W, Ogita H, Fujita N, Takai Y. The roles of nectins in cell adhesions: cooperation with other cell adhesion molecules and growth factor receptors. Curr Opin Cell Biol. 2007;19:593–602.CrossRefPubMed
15.
Yasumi M, Shimizu K, Honda T, Takeuchi M, Takai Y. Role of each immunoglobulin-like loop of nectin for its cellcell adhesion activity. Biochem Biophys Res Commun. 2003;302:61–6.CrossRefPubMed
16.
Yamada A, Fujita N, Sato T, Okamoto R, Ooshio T, Hirota T, et al. Requirement of nectin, but not cadherin, for formation of claudin-based tight junctions in annexin II-knockdown MDCK cells. Oncogene. 2006;25:5085–102.CrossRefPubMed
17.
Takai Y, Nakanishi H. Nectin and afadin: novel organizers of intercellular junctions. J Cell Sci. 2003;116:17–27.CrossRefPubMed
18.
Fukuhara A, Irie K, Yamada A, Katata T, Honda T, Shimizu K, et al. Role of nectin in organization of tight junctions in epithelial cells. Genes Cells. 2002;7:1059–72.CrossRefPubMed
19.
Fukuhara A, Irie K, Nakanishi H, Takekuni K, Kawakatsu T, Ikeda W, et al. Involvement of nectin in the localization of junctional adhesion molecule at tight junctions. Oncogene. 2002;21:7642–55.CrossRefPubMed
20.
Fukuhara A, Shimizu K, Kawakatsu T, Fukuhara T, Takai Y. Involvement of nectin-activated Cdc42 small G protein in organization of adherens and tight junctions in Madin–Darby canine kidney cells. J Biol Chem. 2003;278:51885–93.CrossRefPubMed
21.
Morita H, Nandadasa S, Yamamoto TS, Terasaka-Iioka C, Wylie C, Ueno N. Nectin-2 and N-cadherin interact through extracellular domains and induce apical accumulation of F-actin in apical constriction of Xenopus neural tube morphogenesis. Development. 2010;137:1315–25.PubMedCentralCrossRefPubMed
22.
Matsushima H, Utani A, Endo H, Matsuura H, Kakuta M, Nakamura Y, et al. The expression of nectin-1alpha in normal human skin and various skin tumours. Br J Dermatol. 2003;148:755–62.CrossRefPubMed
23.
24.
Malafosse R, Penna C, Sa Cunha A, Nordlinger B. Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol. 2001;12:887–94.CrossRefPubMed
25.
Aslam MI, Taylor K, Pringle JH, Jameson JS. MicroRNAs are novel biomarkers of colorectal cancer. Br J Surg. 2009;96:702–10.CrossRefPubMed
26.
Miyoshi J, Takai Y. Nectin and nectin-like molecules: biology and pathology. Am J Nephrol. 2007;27:590–604.CrossRefPubMed
27.
Takai Y, Miyoshi J, Ikeda W, Ogita H. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol. 2008;9:603–15.CrossRefPubMed
28.
Martin TA, Lane J, Harrison GM, Jiang WG. The expression of the Nectin complex in human breast cancer and the role of Nectin-3 in the control of tight junctions during metastasis. PLoS ONE. 2013;8:e82696.PubMedCentralCrossRefPubMed
29.
Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A, et al. Analysis of the receptor ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood. 2005;105:2066–73.CrossRefPubMed
30.
Sanchez-Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S, Solana R, et al. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol. 2012;90:109–15.CrossRefPubMed
31.
El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007;67:8444–9.CrossRefPubMed
32.
Oshima T, Sato S, Kato J, Ito Y, Watanabe T, Tsuji I, et al. Nectin-2 is potential target for antibody therapy of breast and ovarian cancers. Mol Cancer. 2013;12:60.PubMedCentralCrossRefPubMed
33.
Miao X, Yang ZL, Xiong L, Zou Q, Yuan Y, Li J, et al. Nectin-2 and DDX3 are biomarkers for metastasis and poor prognosis of squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. Int J Clin Exp Pathol. 2013;6:179–90.PubMedCentralPubMed
34.
Raveh S, Gavert N, Spiegel I, Ben-Ze’ev A. The cell adhesion nectin-like molecules (Necl) 1 and 4 suppress the growth and tumorigenic ability of colon cancer cells. J Cell Biochem. 2009;108(1):326–36.CrossRefPubMed
Metadata
Title
Serum nectin-2 levels are diagnostic and prognostic in patients with colorectal carcinoma
Authors
M. Karabulut
M. Gunaldi
H. Alis
C. U. Afsar
S. Karabulut
M. Serilmez
C. Akarsu
H. Seyit
N. F. Aykan
Publication date
01-02-2016
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 2/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1348-1

Other articles of this Issue 2/2016

Clinical and Translational Oncology 2/2016 Go to the issue

Research Article

Expression and clinical significance of cortactin protein in ovarian neoplasms

Research Article

VEGFR2 inhibition by RNA interference affects cell proliferation, migration, invasion, and response to radiation in Calu-1 cells

Research Article

A cross-sectional assessment of quality of life of colorectal cancer patients in Saudi Arabia

Research Article

Targeting thiamine-dependent enzymes for metabolic therapies in oral squamous cell carcinoma?

Brief Research Article

Watch the weathercock: changes in re-staging 18F-FDG PET/CT scan predict the probability of relapse in locally advanced non-small cell lung cancer

Research Article

Yes-associated protein (YAP) expression is involved in epithelial–mesenchymal transition in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits